Skip to content

TRIM28 facilitates diffuse large B-cell lymphoma progression by inducing glycolytic reprogramming through the E2F1/PKM2 axis.

Sep 2026 · Naunyn-Schmiedeberg's Archives of Pharmacology · 0 citations · 21 references
Medicine

TL;DR

Collectively, TRIM28 facilitates DLBCL progression by inducing glycolytic reprogramming through the E2F1/PKM2 axis, highlighting a potential therapeutic target.

View source

Similar papers

Open access Sep 2026

UPF1-dependent glycolysis driven by LINC00887 facilitates macrophage M2 polarization in clear cell renal cell carcinoma

Introduction LINC00887 plays critical roles in tumor biology, from oncogenesis to metastasis and drug resistance, while the specific mechanism in ccRCC remains unclear. We analyzed the expression profiles of LINC00887 and UPF1 and assessed their correlation with glycolytic activity and M2 macrophage infiltration. Metho...

Jia-Yue Wu, Jia-Wen Wang, Jing-Yu Weng et al. · 0 citations
Open access Oct 2026

Circular RNA circ_0006523 promotes lipid accumulation and proliferation of diffuse large B-cell lymphoma via the miR-659-3p/SPHK1 axis

Dysregulated lipid metabolism is a core hallmark of diffuse large B-cell lymphoma (DLBCL), while the upstream non-coding RNA regulatory network targeting sphingosine kinase 1 (SPHK1), a key lipogenic kinase, remains largely uncharacterized in DLBCL. Here, we identified and validated a novel ceRNA regulatory axis co...

Qi-Xiang Zhou, Yu-Bo Yang, Xing-Yan Guo et al. · 0 citations
Open access Sep 2026

PRMT7‐mediated arginine methylation of FOXK activates Wnt/β‐catenin signalling to drive doxorubicin resistance in diffuse large B‐cell lymphoma

Abstract Background Doxorubicin, an anthracycline chemotherapeutic agent, is widely used in diffuse large B‑cell lymphoma (DLBCL) treatment, yet its clinical efficacy is often compromised by drug resistance. Protein arginine methyltransferase 7 (PRMT7) is a methyltransferase implicated in tumourigenesis and cancer prog...

Xiao-Yan Zhao, J. Zhang, Yao Teng et al. · 0 citations
Sep 2026

PHB2 Promotes Glycolytic Reprogramming in Triple-Negative Breast Cancer Through FOXM1-Dependent Activation of LDHB.

Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its aggressive phenotype and the limited availability of molecularly targeted therapies. In this study, we investigated the therapeutic potential of targeting PHB2 in TNBC by combining bioinformatics analysis with comprehensive in vitr...

Zan-Kai Wu, Shan-Shan Wang, Qing-Feng Yang et al. · 0 citations
Open access Aug 2026

Epigenetically driven GAS2L3 enforces non-canonical cell cycle progression to promote osimertinib resistance in lung adenocarcinoma

These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...

Shu-Man Zhen, Xiaohui Bai, Shu-Tang Liu et al. · 0 citations
Sep 2026

Glut1 and MCT4 cooperatively promote ccRCC cell proliferation and are associated with glycolytic reprogramming and immune-related alterations.

Clear cell renal cell carcinoma (ccRCC) is characterized by glycolytic reprogramming and a lactate-rich tumor microenvironment. We integrated multi-omics, single-cell, tissue microarray, and in vitro analyses to investigate the roles of Glut1 and MCT4 in ccRCC. Both transporters were upregulated at the mRNA and protein...

Kun Cui, Yu-Zhi Zhu, Yue-Li Ni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.